[{"id":"4346ba5f-67b8-4706-8e12-549591ad58c7","acronym":"","url":"https://clinicaltrials.gov/study/NCT06696768","created_at":"2025-02-25T20:15:51.863Z","updated_at":"2025-02-25T20:15:51.863Z","phase":"Phase 1","brief_title":"Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer","source_id_and_acronym":"NCT06696768","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" IFNG • IL6 • CCL2 • CXCL1 • IRAK4","pipe":"","alterations":" ","tags":["IFNG • IL6 • CCL2 • CXCL1 • IRAK4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • oxaliplatin • Aybintio (bevacizumab biosimilar) • leucovorin calcium • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • emavusertib (CA-4948) • fluorouracil topical"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 02/28/2025","start_date":" 02/28/2025","primary_txt":" Primary completion: 10/31/2025","primary_completion_date":" 10/31/2025","study_txt":" Completion: 10/31/2025","study_completion_date":" 10/31/2025","last_update_posted":"2025-01-16"}]